172 related articles for article (PubMed ID: 30927708)
1. Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
Zhan JY; Ma J; Zheng QC
J Mol Graph Model; 2019 Jun; 89():242-249. PubMed ID: 30927708
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
[TBL] [Abstract][Full Text] [Related]
3. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Manley PW; Barys L; Cowan-Jacob SW
Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
[TBL] [Abstract][Full Text] [Related]
4. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
[TBL] [Abstract][Full Text] [Related]
5. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D; Hughes TP
Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
[TBL] [Abstract][Full Text] [Related]
6. A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.
Manley PW; Huth F; Moussaoui S; Schoepfer J
Bioorg Med Chem Lett; 2022 Mar; 59():128577. PubMed ID: 35065232
[TBL] [Abstract][Full Text] [Related]
7. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
[TBL] [Abstract][Full Text] [Related]
8. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
El Rashedy AA; Olotu FA; Soliman MES
Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229
[TBL] [Abstract][Full Text] [Related]
9. The Perplexity of Synergistic Duality: Inter-molecular Mechanisms of Communication in BCR-ABL1.
Elrashedy AA; Ramharack P; Soliman MES
Anticancer Agents Med Chem; 2019; 19(13):1642-1650. PubMed ID: 31250767
[TBL] [Abstract][Full Text] [Related]
10. Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
Yang Y; Gao H; Sun X; Sun Y; Qiu Y; Weng Q; Rao Y
J Med Chem; 2020 Aug; 63(15):8567-8583. PubMed ID: 32657579
[TBL] [Abstract][Full Text] [Related]
11. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
Oruganti B; Lindahl E; Yang J; Amiri W; Rahimullah R; Friedman R
J Biol Chem; 2022 Aug; 298(8):102238. PubMed ID: 35809644
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
[TBL] [Abstract][Full Text] [Related]
13. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
Yeung DT; Shanmuganathan N; Hughes TP
Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
[TBL] [Abstract][Full Text] [Related]
14. How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study.
Zhang H; He X; Ni D; Mou L; Chen X; Lu S
J Biomol Struct Dyn; 2020 Jan; 38(1):89-100. PubMed ID: 30661457
[TBL] [Abstract][Full Text] [Related]
15. A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR-ABL1 Resistance.
El Rashedy AA; Appiah-Kubi P; Soliman MES
Protein J; 2019 Apr; 38(2):142-150. PubMed ID: 30877503
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
Qiang W; Antelope O; Zabriskie MS; Pomicter AD; Vellore NA; Szankasi P; Rea D; Cayuela JM; Kelley TW; Deininger MW; O'Hare T
Leukemia; 2017 Dec; 31(12):2844-2847. PubMed ID: 28819281
[No Abstract] [Full Text] [Related]
17. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
Banavath HN; Sharma OP; Kumar MS; Baskaran R
Sci Rep; 2014 Nov; 4():6948. PubMed ID: 25382104
[TBL] [Abstract][Full Text] [Related]
18. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
19. Asciminib for chronic myeloid leukaemia: Next questions.
Shanmuganathan N; Hughes TP
Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
[TBL] [Abstract][Full Text] [Related]
20. Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.
Lin HC; Saputra F; Audira G; Lai YH; Roldan MJM; Alos HC; Aventurado CA; Vasquez RD; Tsai GJ; Lim KH; Hsiao CD
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
